- Kolosis bone grafts continue gaining substantial market presence, now available in over 450 hospitals and surgical facilities across 48 states
- Kore Fiber and Prime HD grafts utilized in over 16,000 fusion procedures in 2023, a 33% increase from the previous year.
- Kolosis BIO channel partners now topping more than 200 independent distributors in the spine and orthopedic space
- Expanded partnership with MTF into the Surgical Wound Market
- A Utah Fast 50 Emerging Company for FY2023
SALT LAKE CITY, UTAH — Kolosis BIO, LLC (Kolosis), a Salt Lake City based biologics company and exclusive partner to MTF Biologics, proudly announces its 2023 results as it looks towards expected 2024 performance.
Kolosis leadership recognizes the impressive gains made by the company over the past year. “I couldn’t be more excited about our progress over the past year and seeing our tissues become a trusted choice in over 450 hospitals across the country,” said Collin Begley, CEO of Kolosis. “This success speaks volumes about the potential of our disruptive technologies.”